--- title: "Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results" description: "U.S. stocks rose, with the Dow Jones up over 200 points, while Cleveland-Cliffs shares surged 17% after Q3 results. The Dow gained 0.47%, NASDAQ 0.93%, and S&P 500 0.61%. Energy stocks increased by 1." type: "news" locale: "en" url: "https://longbridge.com/en/news/261908212.md" published_at: "2025-10-20T13:50:03.000Z" --- # Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results > U.S. stocks rose, with the Dow Jones up over 200 points, while Cleveland-Cliffs shares surged 17% after Q3 results. The Dow gained 0.47%, NASDAQ 0.93%, and S&P 500 0.61%. Energy stocks increased by 1.2%, while consumer staples fell by 0.1%. Notable gainers included Replimune Group (+105%) and Celcuity Inc. (+55%). In commodities, oil fell 1.2%, gold rose 2.8%, and European markets also saw gains. Asian markets closed higher, with Japan's Nikkei 225 up 3.37%. U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday. Following the market opening Tuesday, the Dow traded up 0.47% to 46,407.15 while the NASDAQ gained 0.93% to 22,890.22. The S&P 500 also rose, gaining, 0.61% to 6,704.61. Check This Out: Top 2 Tech Stocks That May Fall Off A Cliff This Month **Leading and Lagging Sectors** Energy shares jumped by 1.2% on Monday. In trading on Monday, consumer staples stocks fell by 0.1%. **Top Headline** **Cleveland-Cliffs Inc**. (NYSE:CLF) shares jumped around 17% on Monday after the company reported third-quarter 2025 results. The steelmaker reported an adjusted loss of 45 cents per share, beating analysts' expectations for a 48-cent loss. Revenue totaled $4.73 billion, missing the consensus estimate of $4.90 billion but up from $4.57 billion in the same quarter last year. **Equities Trading UP ** - **Replimune Group, Inc.** (NASDAQ:REPL) shares shot up 105% to $9.31 after the FDA accepted the company’s resubmission of the Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, with a PDUFA date of April 10, 2026. - Shares of **Celcuity Inc.** (NASDAQ:CELC) got a boost, surging 55% to $80.50 after the company presented Phase 1 data at ESMO 2025 showing its gedatolisib plus darolutamide combination delivered a 9.1-month median rPFS in mCRPC with a favorable safety profile and no treatment-related discontinuations. - **GSI Technology, Inc.** (NASDAQ:GSIT) shares were also up, gaining 70% to $8.64 after the company said its associative processing uni compute-in-memory architectures can match GPU-level performance for large-scale AI applications. **Equities Trading DOWN** - **MingZhu Logistics Holdings Limited** (NASDAQ:YGMZ) shares dropped 78% to $0.1962. - Shares of **Adaptimmune Therapeutics plc** (NASDAQ:ADAP) were down 71% to $0.0586 after the company announced it will delist from the Nasdaq. - **United Homes Group, Inc.** (NASDAQ:UHG) was down, falling 39% to $2.5944. United Homes Group announced conclusion of review of strategic alternatives and resignation of directors. **Commodities** In commodity news, oil traded down 1.2% to $56.88 while gold traded up 2.8% at $4,330.00. Silver traded up 2.1% to $51.165 on Monday, while copper rose 0.8% to $5.0105. **Euro zone** European shares were higher today. The eurozone's STOXX 600 rose 0.8%, while Spain's IBEX 35 Index rose 1.4%. London's FTSE 100 rose 0.4%, Germany's DAX 40 gained 1.6% and France's CAC 40 rose 0.2% during the session. **Asia Pacific Markets** Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 3.37%, Hong Kong's Hang Seng index surging 2.42%, China's Shanghai Composite gaining 0.63% and India's BSE Sensex rising 0.49%. **Economics** The CB Leading Index will be released today. **Now Read This:** - **How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q3 Earnings** Photo via Shutterstock ### Related Stocks - [CLF.US - Cleveland Cliffs](https://longbridge.com/en/quote/CLF.US.md) - [CELC.US - Celcuity](https://longbridge.com/en/quote/CELC.US.md) - [REPL.US - Replimune](https://longbridge.com/en/quote/REPL.US.md) - [TGT.US - Target](https://longbridge.com/en/quote/TGT.US.md) - [COST.US - Costco Wholesale](https://longbridge.com/en/quote/COST.US.md) - [KR.US - Kroger](https://longbridge.com/en/quote/KR.US.md) - [YCS.US - Pro Ultrshrt Yen](https://longbridge.com/en/quote/YCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Cleveland-Cliffs Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts | Cleveland-Cliffs Inc. (NYSE:CLF) is set to release its Q4 earnings on Feb. 9, with analysts predicting a loss of 62 cent | [Link](https://longbridge.com/en/news/275278839.md) | | Maple Rock Capital Partners Inc. Makes New Investment in Cleveland-Cliffs Inc. $CLF | Maple Rock Capital Partners Inc. invested in Cleveland-Cliffs Inc., acquiring 8,385,600 shares worth $63,731,000, making | [Link](https://longbridge.com/en/news/269524646.md) | | Target to test contextual ads in ChatGPT, including through Roundel | Target will pilot contextual ads in ChatGPT, promoting its business and brand partners through its Roundel retail media | [Link](https://longbridge.com/en/news/276008317.md) | | Life after the Great Resignation: Incentives are dimming for workers to change jobs | The labor market is experiencing a shift post-Great Resignation, with a significant decline in job quits and a narrowing | [Link](https://longbridge.com/en/news/276373489.md) | | What 21 Analyst Ratings Have To Say About Target | 21 analysts have evaluated Target (NYSE:TGT) over the past three months, showing mixed sentiments. The average 12-month | [Link](https://longbridge.com/en/news/276133373.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.